Clinical Trials on Chronic Myeloproliferative Neoplasms in France

Total 13730 results

Institut National de la Santé Et de la Recherche...

Recruiting

Mechanism of Action of Interferon in the Treatment of Myeloproliferative Neoplasms (IFN&SMP)

Myeloproliferative Neoplasm

France
Groupe Francophone des Myelodysplasies
Aprea Therapeutics

Unknown

Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine

Chronic Myelomonocytic Leukemia | Myeloproliferative Neoplasm | Acute Myeloid Leukemia With Gene Mutations | Myelodysplastic Syndrome With Gene Mutation

France
Lille Catholic University

Completed

Role of the Circulating Procoagulants Microparticles in the Hypercoagulability of MNP Ph1- (MICROP-SMP)

Myeloproliferative Neoplasm

France
University Hospital, Bordeaux

Recruiting

Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC) (EpiC)

Myeloproliferative Neoplasm

France
University Hospital, Brest

Unknown

Aquagenic Pruritus in Myeloproliferative Neoplasms (PANAM)

Deciphering Aquagenic Pruritus in Myeloproliferaitive Neoplasms

France
Institut Paoli-Calmettes

Completed

Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

France
University Hospital, Bordeaux

Recruiting

Role of Monocytes Sub-populations in Thrombosis Associated With Myeloproliferative Neoplasms (MonSThr) (MonSThr)

Myeloproliferative Neoplasm

France
Hybrigenics Corporation

Unknown

Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study (ICT10)

CML, Chronic Phase

France
Institut Bergonié
Novartis

Terminated

Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response (MIM)

Leukemia, Myeloid, Chronic-Phase

France
Hospices Civils de Lyon

Unknown

AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year

Chronic Myeloid Leukemia

France
University Hospital, Angers

Active, not recruiting

Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality (PALERMO)

Chronic Myeloid Leukemia (CML)

France
Hospices Civils de Lyon
Novartis

Unknown

Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients (PETALs)

Chronic Myeloid Leukemia

France
Poitiers University Hospital
Novartis

Completed

Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years

Chronic Myeloid Leukemia

France
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis

Chronic Myeloproliferative Disorders

United States, United Kingdom, France
Hospices Civils de Lyon

Completed

Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia (NILOPEG)

Chronic Myelogenous Leukemia

France
Novartis Pharmaceuticals

Completed

French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients

Chronic Myeloid Leukemia

France
Poitiers University Hospital
Novartis

Completed

Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation

Chronic Myeloid Leukemia

France
Poitiers University Hospital
Novartis; Ministry of Health, France

Terminated

Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients

Chronic Myeloid Leukemia

France
Fondazione per la Ricerca Ospedale Maggiore

Completed

Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms (MPN-DOACs)

Myeloproliferative Neoplasm

Italy, United Kingdom, Germany, France, United States, Spain, Canada
Centre Hospitalier Universitaire de Besancon

Completed

Study of Predictive Immunological Parameters of Molecular Complete Remission in Patients With Chronic Myelogenous Leukemia in Chronic Phase and Treated With Tyrosine Kinase Inhibitor (PAMIR01)

Chronic Leukemia

France
Bristol-Myers Squibb

Completed

A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating Dasatinib in a Real Life Setting

Chronic Myeloid Leukemia

France
University Hospital, Bordeaux
Bordeaux PharmacoEpi

Completed

Budget Impact Analysis of Discontinuing Tyrosin Kinase Inhibitors in Patients With Chronic Myeloid Leukemia Achieving a Complete Molecular Response by Using Probabilistic Markov Approach (ECOSTIM)

Hematologic Diseases | Chronic Myeloid Leukemia

France
Poitiers University Hospital
Novartis; Roche Pharma AG; Ministry of Health, France

Completed

STI571 ProspectIve RandomIzed Trial: SPIRIT (SPIRIT)

Chronic Myeloid Leukemia

France
Centre Hospitalier Universitaire de Besancon

Completed

Targeting Leukemic Stem Cell Expressing the IL-1RAP Protein in Chronic Myelogenous Leukemia (CML) (CAR-LMC)

Chronic Myeloid Leukemia

France
Centre Hospitalier Universitaire de Saint Etienne
Institut de Cancérologie de la Loire

Recruiting

Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia (PHARM-LMC)

Chronic Myeloid Leukemia

France
Groupe Francophone des Myelodysplasies
AbbVie

Recruiting

Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) (AVENHIR)

Chronic Myeloid Leukemia

France
Children's Oncology Group
National Cancer Institute (NCI)

Completed

INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease

Unspecified Childhood Solid Tumor, Protocol Specific | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Myelodysplastic/Myeloproliferative Neoplasms

United States
Centre Hospitalier Universitaire de Nīmes

Withdrawn

Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms (abl LMC)

Leukemia, Myeloid, Chronic-Phase

France
University Hospital, Angers

Completed

Vascular Dysfunction and Antiangiogenic Therapy (DYVA-AAGG)

Solid Tumor | Endothelial Dysfunction | Tumor Angiogenesis | CML (Chronic Myelogenous Leukemia)

France
Assistance Publique - Hôpitaux de Paris

Unknown

Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Disorders (CTIM3)

Myeloproliferative Neoplasms

France
Poitiers University Hospital

Completed

Glivec in Pediatric Chronic Myeloid Leukemia (CML)

Chronic Myeloid Leukemia

France
University Hospital, Bordeaux

Recruiting

CML Pediatric ITK Response According to Molecular Identification at Diagnosis (CML Piramid)

Chronic Myeloid Leukemia

France
Institut Bergonié

Recruiting

Regional Central Database Recording of Chronic Myeloid Leukemia (LMC)

Chronic Myeloid Leukemia

France
Centre Hospitalier Universitaire de Nice

Unknown

Relevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia (CMML)

Chronic Myelomonocytic Leukemia

France
Institut Bergonié
Novartis

Terminated

Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response (AFR22)

Myeloid Leukemia, Chronic

France
Versailles Hospital
Pr Philippe ROUSSELOT

Unknown

Second STOP After Pioglitazone Priming in CML Patients (PIO2STOP)

Chronic Myeloid Leukemia (CML)

France
Versailles Hospital

Completed

Pioglityazone and Imatinib for CML Patients (ACTIM)

Leukemia, Myeloid, Chronic-Phase

France
Novartis Pharmaceuticals

Recruiting

Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France (ASSURE-3)

Chronic Myeloid Leukemia

France
Poitiers University Hospital

Active, not recruiting

Innate T Cells and TKI Discontinuation (TIBIOP-LMC)

Chronic Myeloid Leukemia

France
Eli Lilly and Company
Loxo Oncology, Inc.

Active, not recruiting

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS) | Myeloproliferative Neoplasms (MPNs)

United States, Spain, Korea, Republic of, France, Taiwan, Australia, Belgium, Singapore, Israel, Canada, Germany, Finland
Centre Hospitalier Universitaire de Nīmes

Active, not recruiting

Functional Characterization of Thrombopoietin/cMPL Receptor Mutations in Myeloproliferative Neoplasia (MPL - NPM)

Myeloproliferative Disorder

France
Bayer

Completed

Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec (ORACLE)

Chronic Myelogenous Leukemia

United States, France
University Hospital, Bordeaux

Recruiting

Determination of the Clonality Profile in Myeloproliferative Neoplasms and Association With the Thrombotic Complications (CLOJAK) (CLOJAK)

Myeloproliferative Neoplasm

France
CTI BioPharma
National Cancer Institute (NCI)

Terminated

Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Assistance Publique - Hôpitaux de Paris

Recruiting

The Patient Cohort of the National Center for Precision Medicine in Leukemia (eTHEMA)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | High-risk Myelodysplastic Syndrome | Myeloproliferative Neoplasm, Unclassifiable | Secondary Myelofibrosis in Myeloproliferative Disease

France
University Hospital, Angers

Not yet recruiting

Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes (PHEMOP)

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myeloproliferative Neoplasm

France
National Cancer Institute (NCI)

Recruiting

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Myelodysplastic Syndrome With Excess Blasts | Myeloproliferative Neoplasm

United States, Canada
University Hospital, Bordeaux

Completed

Evaluation of New Biomarkers of Thrombosis in Myeloproliferative Neoplasms (MPN-BIOCLOT)

Myeloproliferative Neoplasm

France
Centre Hospitalier Henri Duffaut - Avignon

Recruiting

Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia (IPA-LMC)

Chronic Myelogenous Leukemia - Chronic Phase

France
AbbVie

Active, not recruiting

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

Myeloproliferative Neoplasm

United States, Belgium, Bulgaria, Croatia, France, Germany, Italy, Japan, Serbia, Spain, Sweden, Taiwan, Turkey, United Kingdom

Clinical Trials on Chronic Myeloproliferative Neoplasms in France

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations